Health Press Barbados: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Press Barbados.

Press releases published on June 22, 2026

Jun. 22, 2026

Next-Generation DNA Repair Therapies Open New Frontiers in Oncology

Indeterminate GlobeNewswire

Jun. 22, 2026

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis

Indeterminate GlobeNewswire

Jun. 22, 2026

FibroBiologics Receives Notice of Allowance for U.S. Patent Covering Topical Fibroblast Spheroid Therapy for Wound Healing

Indeterminate GlobeNewswire

Jun. 22, 2026

Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis

Indeterminate GlobeNewswire

Jun. 22, 2026

NewGen Issues 3,666,667 New Shares in Connection with Strategic K25.ai Acquisition, Reaches Milestone of US$7.6 Million Market Capitalization

Indeterminate GlobeNewswire

Jun. 22, 2026

Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity

Indeterminate GlobeNewswire

Jun. 22, 2026

Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial

Indeterminate GlobeNewswire

Jun. 22, 2026

Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts 

Indeterminate GlobeNewswire

Jun. 22, 2026

Novel Key Terms For Managing CIDP Published in Neurology® Journal

Indeterminate GlobeNewswire

Jun. 22, 2026

Medidata Unveils New Academic Board to Bridge the Gap Between Research and Patient Care

Indeterminate GlobeNewswire

Jun. 22, 2026

Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition

Indeterminate GlobeNewswire

Jun. 22, 2026

GuideAI Health Receives FDA 510(k) Clearance for VascularAssist Occlusion Triage

Indeterminate GlobeNewswire

Jun. 22, 2026

Autonomix Medical Announces Standalone Neural Sensing Program with Evidence of Real-Time Renal Nerve Activity Change

Indeterminate GlobeNewswire

Jun. 22, 2026

Hyperion DeFi and Blockdaemon Partner to Expand Institutional Hyperliquid Staking Infrastructure

Indeterminate GlobeNewswire

Jun. 22, 2026

Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D.

Indeterminate GlobeNewswire

Jun. 22, 2026

Nasus Pharma to Participate in the Zacks Life Sciences Investor Forum

Indeterminate GlobeNewswire

Jun. 22, 2026

Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

Indeterminate GlobeNewswire

Jun. 22, 2026

Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome

Indeterminate GlobeNewswire

Jun. 22, 2026

Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants

Indeterminate GlobeNewswire

Jun. 22, 2026

Atsena Therapeutics Doses First Patient and Reports Rapid Early Enrollment in Pivotal Trial of ATSN-201 for X-Linked Retinoschisis

Indeterminate GlobeNewswire